RCGP curriculum - Introducing the GP curriculum
Dr Ben Riley and Dr Jayne Haynes explain what the curriculum is and why it is necessary. Read more
The survey of 155 GPs showed that 47 per cent of GPs wanted obesity to be dropped. A quarter wanted learning difficulties and chronic kidney disease removed from the framework. Twelve per cent rejected the smoking indicators.
Scottish LMCs voted in April 2007 for obesity to be dropped from the quality framework because it is a lifestyle issue.
The survey also highlighted that 34 per cent of GPs wanted changes to the way in which the quality framework deals with obesity, if it remains an indicator.
Hertfordshire GP Dr David Haslam, clinical director of the National Obesity Forum, described the obesity domain, worth eight points and introduced in 2006/7, as ‘worse than useless.'
'I sympathise with the GPs who want obesity to be dropped, because the current indicator is of no clinical benefit at all. All it does is elevate all obese patients to the same status,' he said.
GPC deputy chairman Dr Laurence Buckman said that the indicator for obesity was a meaningless device that was included in the quality framework simply to please politicians.
'It is the only indicator in the quality framework that is not supported by clinical evidence,' he said.
Dr Haslam said that it was essential that obesity remained in the quality framework.
'We need to be screening the patients on the obesity register for diabetes, hypertension, stroke and heart disease,' he said.
What do you think? Comment below or email healthcare.republic@haymarket.com
Dr Ben Riley and Dr Jayne Haynes explain what the curriculum is and why it is necessary. Read more
Greater awareness of drinking problems is needed, say Professor Eileen Kaner and Ruth McGovern. Read more
Dr Sathya Naidoo explains the criteria that are required for completing iMAP. Read more
Contributed by Dr Matthew Litchfield, GP, Nottingham and Dr James Milledge, retired consultant respi... Read more
Contributed by Mr David Walker, consultant obstetrician and gynaecologist at the Royal United Hospit... Read more
Contributed by Dr Unni Krishnan, clinical research fellow in cardiology at the Glenfield Hospital, L... Read more
GSK has launched Volibris (ambrisentan) for the treatment of pulmonary arterial hypertension (WHO Cl... Read more
Thymoglobuline is an immunosuppressant for the prophylaxis of graft rejection in renal or heart tra... Read more
Tyverb (lapatinib) is an oral antineoplastic agent that may provide women with an alternative option... Read more
Comments
Only registered users may comment. Log in now or register for a free account.